课题基金 / 基金详情

Canadian HIV Cure Enterprise 2.0: Targeting the interplay between myeloid cells and CD4+ T-cells for HIV cure

Canadian HIV Cure Enterprise 2.0: Targeting the interplay between myeloid cells and CD4+ T-cells for HIV cure
加拿大 HIV 治愈企业 2.0：针对骨髓细胞和 CD4 T 细胞之间的相互作用进行 HIV 治愈
批准号：
404213
负责人：
Cohen Eric A
金额：
$437.1万
依托单位：
Institut de recherches cliniques de Montral
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2018
资助国家：
加拿大
项目状态：
已结题
起止时间：
2018-11-01 至 2023-11-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=404213&lang=en
关键词：
Hiv Cure Hiv Latency Hiv Persistence Hiv Reservoirs Human Studies Humanized Mouse Models Memory Cd4+ T-Cells Myeloid Cells Non-Human Primate Model Therapeutic Interventions

项目摘要

项目成果

Cohen Eric A的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Despite the success of antiretroviral therapy (ART) in decreasing mortality for HIV-infected individuals, ART has not cured HIV/AIDS. The failure to eradicate HIV infection during ART stems from the virus' ability to persist in the body in multiple cell t
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting of host antiviral and immune-modulatory factors by HIV-1 Vpu: Implications for viral pathogenesis and therapy
Examining the role of plasmacytoid dendritic cells in the control of HIV infection using humanized mice
Human immunodeficiency virus (HIV)-host interactions: from mechanisms of viral persistence to infection control
Plasmacytoid dendritic cells in HIV infection
海外基金